Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Radboud University Medical Center
With
Dutch Cancer Society
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject is able and willing to sign the Informed Consent Form
Age 18 years or older
WHO performance status 0-2
Life expectancy ≥ 12 weeks
mRCC patients in which the treatment of choice is sunitinib
You may not be if
Use of corticosteroids
Any evidence of severe or uncontrolled diseases other than renal cell carcinoma eg, unstable or uncompensated respiratory, cardiac, hepatic or renal disease.
Known risk of the patient transmitting HIV, hepatitis B or C via infected blood
Patients being treated with oral anticoagulants if to be included in group A.
Clareo Health | The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
